Leap Therapeutics (LPTX) Competitors $0.32 +0.01 (+2.62%) Closing price 04:00 PM EasternExtended Trading$0.31 -0.01 (-2.65%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. DTIL, LTRN, PEPG, NBRV, RNXT, ATHE, AADI, ANVS, GRCE, and JSPRShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), Lantern Pharma (LTRN), PepGen (PEPG), Nabriva Therapeutics (NBRV), RenovoRx (RNXT), Alterity Therapeutics (ATHE), Aadi Bioscience (AADI), Annovis Bio (ANVS), Grace Therapeutics (GRCE), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. Its Competitors Precision BioSciences Lantern Pharma PepGen Nabriva Therapeutics RenovoRx Alterity Therapeutics Aadi Bioscience Annovis Bio Grace Therapeutics Jasper Therapeutics Leap Therapeutics (NASDAQ:LPTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership. Which has more risk & volatility, LPTX or DTIL? Leap Therapeutics has a beta of -0.21, indicating that its stock price is 121% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Do analysts rate LPTX or DTIL? Leap Therapeutics currently has a consensus price target of $3.38, indicating a potential upside of 963.33%. Precision BioSciences has a consensus price target of $47.00, indicating a potential upside of 906.42%. Given Leap Therapeutics' higher probable upside, equities research analysts clearly believe Leap Therapeutics is more favorable than Precision BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer LPTX or DTIL? In the previous week, Precision BioSciences had 2 more articles in the media than Leap Therapeutics. MarketBeat recorded 3 mentions for Precision BioSciences and 1 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.89 beat Precision BioSciences' score of 0.98 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Leap Therapeutics Very Positive Precision BioSciences Positive Which has stronger earnings and valuation, LPTX or DTIL? Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.58-0.20Precision BioSciences$1.26M43.65$7.17M-$8.81-0.53 Do insiders & institutionals have more ownership in LPTX or DTIL? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by insiders. Comparatively, 4.5% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is LPTX or DTIL more profitable? Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Precision BioSciences' return on equity of -176.47% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -237.65% -155.38% Precision BioSciences -6,205.79%-176.47%-69.05% SummaryPrecision BioSciences beats Leap Therapeutics on 9 of the 15 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.15M$3.08B$5.69B$10.27BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-0.2021.3075.8626.51Price / SalesN/A379.80489.92165.32Price / CashN/A44.4425.8129.89Price / Book0.359.6112.846.32Net Income-$67.56M-$53.28M$3.28B$270.51M7 Day Performance12.39%0.30%0.20%2.15%1 Month Performance18.39%4.57%4.59%6.35%1 Year Performance-89.46%9.23%68.31%25.48% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.7286 of 5 stars$0.32+2.6%$3.38+963.3%-88.7%$13.15MN/A-0.2040Positive NewsDTILPrecision BioSciences4.2099 of 5 stars$4.97-2.0%$47.00+845.7%-56.3%$59.76M$68.70M-0.56200News CoverageLTRNLantern Pharma2.3734 of 5 stars$4.06-5.8%$25.00+515.8%-5.2%$46.54MN/A-2.2820News CoverageGap UpTrading HaltedPEPGPepGen2.8225 of 5 stars$1.49+6.4%$7.67+414.5%-83.2%$45.92MN/A-0.5030NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070RNXTRenovoRx2.3454 of 5 stars$1.14-8.1%$7.50+557.9%+12.8%$45.44M$40K-3.006Short Interest ↑Gap UpATHEAlterity Therapeutics2.5109 of 5 stars$5.17+2.0%$12.00+132.1%+268.3%$44.96MN/A0.0010News CoverageHigh Trading VolumeAADIAadi BioscienceN/A$1.82+0.6%N/A+10.6%$44.95M$25.07M-0.8040ANVSAnnovis Bio2.1109 of 5 stars$2.34+2.1%$17.33+641.4%-69.9%$44.62MN/A-1.153News CoverageGRCEGrace Therapeutics2.9039 of 5 stars$3.24+1.3%$12.00+270.4%N/A$44.25MN/A-3.77N/ANews CoverageAnalyst UpgradeJSPRJasper Therapeutics3.4585 of 5 stars$2.65-2.6%$28.75+984.9%-89.5%$44.21MN/A-0.4420 Related Companies and Tools Related Companies Precision BioSciences Alternatives Lantern Pharma Alternatives PepGen Alternatives Nabriva Therapeutics Alternatives RenovoRx Alternatives Alterity Therapeutics Alternatives Aadi Bioscience Alternatives Annovis Bio Alternatives Grace Therapeutics Alternatives Jasper Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | Sponsored$4?In times like these… it’s almost impossible to find a good deal. That’s why you should check this out. G...Monument Traders Alliance | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LPTX Stock Alerts